U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C23H23NO3
Molecular Weight 361.4336
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of VELIFLAPON

SMILES

OC(=O)[C@H](C1CCCC1)C2=CC=C(OCC3=NC4=C(C=CC=C4)C=C3)C=C2

InChI

InChIKey=ZEYYDOLCHFETHQ-JOCHJYFZSA-N
InChI=1S/C23H23NO3/c25-23(26)22(17-6-1-2-7-17)18-10-13-20(14-11-18)27-15-19-12-9-16-5-3-4-8-21(16)24-19/h3-5,8-14,17,22H,1-2,6-7,15H2,(H,25,26)/t22-/m1/s1

HIDE SMILES / InChI
Veliflapon (BAY X1005, DG-031) is an enantioselective inhibitor of 5-lipoxygenase activating protein, or FLAP. There are variants in the gene encoding FLAP, and the gene encoding leukotriene A4 hydrolase (LTA4H) linked to risk of heart attack. These variants appear to confer increased risk of heart attack by increasing the production of leukotriene B4 (LTB4), a potent driver of inflammation produced in atherosclerotic plaques. deCODE licensed veliflapon (BAY X1005, DG-031) from Bayer AG, which developed it originally for the treatment of asthma.

Approval Year

Targets

Targets

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
VELIFLAPON

Approved Use

Unknown
Primary
VELIFLAPON

Approved Use

Unknown
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer

Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
no
PubMed

PubMed

TitleDatePubMed
Requirement of a 5-lipoxygenase-activating protein for leukotriene synthesis.
1990 Jan 18
Mode of action of the new selective leukotriene synthesis inhibitor BAY X 1005 ((R)-2-[4-(quinolin-2-yl-methoxy)phenyl]-2-cyclopentyl acetic acid) and structurally related compounds.
1993 Jan 7
Pharmacological modulation of human platelet leukotriene C4-synthase.
1997 Mar 21
Leukotriene C4 is a tight-binding inhibitor of microsomal glutathione transferase-1. Effects of leukotriene pathway modifiers.
1999 Jan 22
Inhibition of 5-lipoxygenase activating protein decreases proteinuria in diabetic rats.
2003 Jan-Feb
Interactions among three classes of mediators explain antigen-induced bronchoconstriction in the isolated perfused and ventilated guinea pig lung.
2003 Oct
Inhibition of 5-lipoxygenase induces cell growth arrest and apoptosis in rat Kupffer cells: implications for liver fibrosis.
2003 Sep
Inhibition of 5-lipoxygenase-activating protein abrogates experimental liver injury: role of Kupffer cells.
2005 Oct
5-Lipoxygenase-activating protein (FLAP) inhibitors. Part 4: development of 3-[3-tert-butylsulfanyl-1-[4-(6-ethoxypyridin-3-yl)benzyl]-5-(5-methylpyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethylpropionic acid (AM803), a potent, oral, once daily FLAP inhibitor.
2011 Dec 8
Patents

Sample Use Guides

Patients randomized into 6 treatment sequences; a sequence with DG-031 first and then placebo and a sequence with placebo first and then DG-031 for each of the 3 dosages: 250 mg/d, 500 mg/d, and 750 mg/d. All patients received 3 tablets per day.
Route of Administration: Oral
In Vitro Use Guide
Veliflapon (BAY X1005) effectively inhibits the synthesis of leukotriene B4 (LTB4) in A23187-stimulated leukocytes from rats, mice and humans (IC50 0.026, 0.039 and 0.22 uM, respectively), as well as the formation of leukotriene C4 (IC50 0.021 uM) in mouse peritoneal macrophages stimulated with opsonized zymosan. The compound is, however, less active in inhibiting LTB4 synthesis in human whole blood (IC50 17.0 and 11.6 uM, as measured by RIA or HPLC, respectively). BAY X1005 is shown to be a selective inhibitor of the formation of 5-lipoxygenase-derived metabolites in vitro, without effects on other routes of arachidonic acid metabolism such as 12-lipoxygenase in human whole blood and cyclooxygenase in both mouse macrophages and human whole blood. BAY X1005 is devoid of any antioxidant activity (methemoglobin induction and xanthine-xanthine oxidase assay), without effects on granule release and with only weak effects on reactive oxygen species generation in human polymorphonuclear leukocytes.
Name Type Language
VELIFLAPON
INN   USAN  
INN   USAN  
Official Name English
DG-031
Code English
BAY X-1005
Code English
veliflapon [INN]
Common Name English
BAY-X-1005
Code English
(+)-(2R)-CYCLOPENTYL(QUINOLIN-2-YLMETHOXY)ACETIC ACID
Systematic Name English
BAY X 1005
Code English
BENZENEACETIC ACID, .ALPHA.-CYCLOPENTYL-4-(2-QUINOLINYLMETHOXY)-, (.ALPHA.R)-
Common Name English
VELIFLAPON [USAN]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C78274
Created by admin on Sat Dec 16 16:04:49 GMT 2023 , Edited by admin on Sat Dec 16 16:04:49 GMT 2023
Code System Code Type Description
CAS
128253-31-6
Created by admin on Sat Dec 16 16:04:49 GMT 2023 , Edited by admin on Sat Dec 16 16:04:49 GMT 2023
PRIMARY
FDA UNII
JXH6X663L0
Created by admin on Sat Dec 16 16:04:49 GMT 2023 , Edited by admin on Sat Dec 16 16:04:49 GMT 2023
PRIMARY
PUBCHEM
123723
Created by admin on Sat Dec 16 16:04:49 GMT 2023 , Edited by admin on Sat Dec 16 16:04:49 GMT 2023
PRIMARY
USAN
RR-118
Created by admin on Sat Dec 16 16:04:49 GMT 2023 , Edited by admin on Sat Dec 16 16:04:49 GMT 2023
PRIMARY
SMS_ID
300000034465
Created by admin on Sat Dec 16 16:04:49 GMT 2023 , Edited by admin on Sat Dec 16 16:04:49 GMT 2023
PRIMARY
INN
8738
Created by admin on Sat Dec 16 16:04:49 GMT 2023 , Edited by admin on Sat Dec 16 16:04:49 GMT 2023
PRIMARY
NCI_THESAURUS
C152848
Created by admin on Sat Dec 16 16:04:49 GMT 2023 , Edited by admin on Sat Dec 16 16:04:49 GMT 2023
PRIMARY
EPA CompTox
DTXSID60155843
Created by admin on Sat Dec 16 16:04:49 GMT 2023 , Edited by admin on Sat Dec 16 16:04:49 GMT 2023
PRIMARY
ChEMBL
CHEMBL88712
Created by admin on Sat Dec 16 16:04:49 GMT 2023 , Edited by admin on Sat Dec 16 16:04:49 GMT 2023
PRIMARY